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Abstract
Objectives: Safety and efficacy of mAbs blocking the IL-6 receptor have been established in RA. This is
the first analysis examining safety and tolerability of sarilumab and tocilizumab administered as single or
multiple doses in patients with RA within the same study.
Methods: In ASCERTAIN, patients were randomized 1: 1: 2 to 24 weeks’ double-blind sarilumab 150 or
200 mg every 2 weeks s.c. or tocilizumab 4 mg/kg every 4 weeks i.v., increased to 8 mg/kg if clinically
indicated. In Study 1309, patients were randomized 1: 1: 1: 1 to single-dose open-label sarilumab 150 or
200 mg s.c. or tocilizumab 4 or 8 mg/kg i.v.
Results: In ASCERTAIN, incidence of treatment-emergent adverse events was similar between sarilumab
and tocilizumab. The most common treatment-emergent adverse events were the following: sarilumab:
neutropenia [6 patients (12.2%) in the 150 mg group and 8 (15.7%) in the 200 mg group], nasopharyngitis
[6 (12.2%) and 3 (5.9%)], and injection-site erythema [4 (8.2%) and 4 (7.8%)]; tocilizumab: accidental
overdose [9 (8.8%)], upper respiratory tract infection [7 (6.9%)] and nausea [7 (6.9%)]. Laboratory changes
in both studies included decreased neutrophils and platelets and increased transaminases and lipids. In
Study 1309, incidence of absolute neutrophil count <1.0 giga/l was similar between sarilumab and toci-
lizumab, and occurred more frequently in the higher dose groups. No association between decrease in
absolute neutrophil count and increased incidence of infection was observed in either study.
Conclusion: No clinically meaningful differences in treatment-emergent adverse events were observed
between sarilumab and tocilizumab. Laboratory changes with sarilumab were within the same range as
those with tocilizumab.
Trial registration numbers: ASCERTAIN (NCT01768572); Study 1309 (NCT02097524).
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Rheumatology key messages
. There were no clinically meaningful differences in safety between sarilumab and tocilizumab.
. Laboratory changes observed with sarilumab were within the same range as those observed with tocilizumab.
. Decreases in absolute neutrophil count were not associated with increased infection risk.
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Introduction
The introduction of biologic DMARDs that target inflam-
matory cytokines, such as TNF or IL-6, has greatly ex-
panded therapeutic options for the treatment of RA and
improved treatment outcomes for these patients [13].
One of the key cytokines involved in mediating the
underlying disease pathophysiology and clinical mani-
festations of RA is IL-6. The role of IL-6 in the patho-
physiology of RA is not completely understood;
however, pleiotropic effects of the cytokine have been
correlated with disease activity and joint destruction
[2]. Furthermore, IL-6 may mediate induction of acute-
phase reactants and play a role in activating autoimmune
response [1, 2]. Consistent with these observations,
blockade of IL-6 signalling mitigates the underlying dis-
ease pathophysiology and clinical manifestations of RA
[3]. Subsequently, multiple biologics targeting the IL-6
signalling pathway have been developed for the treat-
ment of RA [48].
Sarilumab and tocilizumab are monoclonal antibodies
directed against the IL-6 receptor (IL-6R). Sarilumab is a
human IgG1 monoclonal antibody that binds specifically
to both soluble and membrane-bound IL-6R, and it has
been shown to inhibit IL-6-mediated signalling through
these receptors [8]. Tocilizumab is a recombinant huma-
nized monoclonal antibody also directed against the IL-6R
[6]. The efficacy of sarilumab and tocilizumab has previ-
ously been demonstrated in patients with moderate-to-
severe RA [9, 10]. ASCERTAIN and Study 1309 are the
first studies in which sarilumab and tocilizumab were eval-
uated within the same study.
The Phase 3 ASCERTAIN study was designed to assess
the safety, tolerability, pharmacokinetics (PK) and
pharmacodynamics (PD) of sarilumab administered s.c.
and tocilizumab administered i.v. in a population of pa-
tients who had an inadequate response to a prior TNF
inhibitor and were receiving conventional synthetic
DMARD (csDMARD) background therapy. The Phase 1b
Study 1309 was designed to assess the PK and PD, as
well as the safety and tolerability, of a single dose of sar-
ilumab s.c. or tocilizumab i.v. in patients with RA who
were receiving background MTX. The safety and tolerabil-
ity assessments of the single-dose study complement the
data from the multiple-dose ASCERTAIN study, and to-
gether allow for a better understanding of the overall
safety profiles of the anti-IL-6R monoclonal antibodies
sarilumab and tocilizumab. These studies were designed
to report multiple- and single-dose safety and tolerability
of sarilumab administered s.c. and of tocilizumab admin-
istered i.v. in adults with RA. No inferential statistics were
planned.
Methods
Study design
ASCERTAIN (NCT01768572) was an international, multicen-
tre, 24-week, randomized, double-blind, double-dummy,
parallel-group, three-arm study assessing the safety and
tolerability of sarilumab and tocilizumab in patients with
RA and inadequate response to or intolerance of TNF in-
hibitor (TNF-IR) receiving background csDMARDs. The pri-
mary objective of ASCERTAIN was to assess the safety
and tolerability of sarilumab and tocilizumab in TNF-IR pa-
tients with RA. Patients were randomized 1: 1: 2 to sarilu-
mab 150 or 200 mg every 2 weeks (q2w) s.c., or tocilizumab
4 mg/kg every 4 weeks (q4w) i.v., which could be increased
to 8 mg/kg if clinically indicated, consistent with US pre-
scribing information at the time of the study (October
2012) [6]. Patients were also allowed to decrease the
dose of tocilizumab from 8 to 4 mg/kg during the course
of the study at the discretion of the investigator. Dose ad-
justments were not allowed for sarilumab. Safety assess-
ments included incidences of treatment-emergent
adverse events (TEAEs), adverse events (AEs) of special
interest, serious AEs, and potentially clinically significant
laboratory abnormalities. During the study, patients
who experienced AEs and prespecified laboratory abnorm-
alities [e.g. decreased absolute neutrophil count (ANC),
decreased platelet count, elevated alanine aminotransfer-
ase (ALT)] could temporarily or permanently discontinue the
study drug in accordance with protocol requirements.
Laboratory assessments were made at predetermined
time points throughout the study (e.g. complete blood
count every 2 weeks).
Study 1309 was a multicentre, 6-week, open-label, par-
allel-group, single-dose safety, PK and PD study of sar-
ilumab and tocilizumab in patients with RA receiving a
stable background of MTX. Patients were randomized
1: 1: 1: 1 to sarilumab 150 mg s.c., sarilumab 200 mg
s.c., tocilizumab 4 mg/kg i.v. or tocilizumab 8 mg/kg i.v.
The primary objective of the study was to describe the
PD of ANC, CRP, IL-6 and soluble IL-6R after a single
dose of sarilumab s.c. or tocilizumab i.v. in patients with
RA receiving a stable dose of MTX. The PK, safety and
tolerability of a single dose of active treatment were sec-
ondary objectives. Changes in ANC were considered as
both a safety parameter and a PD marker as they provide
an indication of immediate effects related to circulating
drug concentrations. Detailed analyses of all PD markers,
PK parameters and the PK/PD relationship will be dis-
cussed in a separate article. Laboratory and safety as-
sessments were performed predose and 1, 4 and 8 h
after study drug administration on day 1; daily through
day 7; every 2 days through day 15; and on days 19, 22,
29 and 43.
Neither ASCERTAIN nor Study 1309 included an s.c.
administration arm for tocilizumab as tocilizumab had
not been approved for s.c. administration when the stu-
dies were designed.
ASCERTAIN and Study 1309 were conducted in
accordance with the principles laid down in the
Declaration of Helsinki and the International Conference
on Harmonisation guidelines for Good Clinical Practice.
All protocols and amendments were submitted to
independent ethics committees and/or institutional
review boards for review and written approval
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(see Acknowledgements for details). Informed consent
was obtained from all patients before the conduct of
any study-related procedures.
Patient population
Eligible patients in both studies were 518 years of age
with an RA diagnosis for 53 months as determined by
the 2010 revised ACR criteria [11] as well as functional
class IIII as categorized by the 1991 revised ACR criteria
[12]. All patients had continuous treatment with one or a
combination of csDMARDs (ASCERTAIN) or with MTX
1025 mg/week (Study 1309) for 512 consecutive weeks
before screening and were on a stable dose for 56
(ASCERTAIN) or 58 consecutive weeks (Study 1309).
Key exclusion criteria included a history of severe systemic
RA (e.g. vasculitis, pulmonary fibrosis); juvenile idiopathic
arthritis or onset of arthritis before age 16; and past or
current autoimmune, inflammatory systemic or localized
joint disease other than RA (Supplementary Table S1, avail-
able at Rheumatology online).
Statistical analysis
There were no formal hypotheses being tested in these
studies and therefore no formal sample-size power calcu-
lations. The sample size for these safety studies was
based on practical considerations and clinical judgement.
In both studies, all randomized patients who received any
study drug were included in the analysis and analysed
according to the treatment received. Data were analysed
using descriptive statistics, and no formal statistical com-
parisons were performed between groups.
Results
Patient demographic and baseline characteristics
Patients enrolled in ASCERTAIN and Study 1309 were
predominantly female (>80% for both studies), with a
mean age of 52 and 55 years, respectively (Table 1).
ASCERTAIN included patients from the USA, South
America, Western Europe, Eastern Europe and Russia
(Supplementary Table S2, available at Rheumatology
online). All patients in Study 1309 were from the USA.
Baseline disease characteristics were generally well
balanced among treatment groups in ASCERTAIN; while
imbalances in disease characteristics were noted in
Study 1309, these were not expected to affect end point
analyses in this single-dose study. The most common re-
corded medical history terms were hypertension (32.2%),
cholecystectomy (10.9%), hypothyroidism (10.4%) and
tonsillectomy (10.4%) in ASCERTAIN, and postmenopause
(49.5%), hypertension (47.5%) and gastrooesophageal
reflux disease (24.8%) in Study 1309.
Patient disposition
In ASCERTAIN, 202 patients were randomized (tocili-
zumab 4/8 mg/kg q4w i.v., n= 102; sarilumab 150 mg
q2w s.c., n= 49; sarilumab 200 mg q2w s.c., n= 51).
While dose adjustments were not allowed for sarilumab,
62 of 102 patients (60.8%) randomized to tocilizumab T
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4 mg/kg q4w in ASCERTAIN increased their dose from 4 to
8 mg/kg q4w at least once during the treatment period
(Supplementary Fig. S1, available at Rheumatology
online); 42 patients (41.2%) increased dose from 4 to
8 mg/kg q4w at week 4. Of the 62 patients who increased
their tocilizumab dose to 8 mg/kg q4w, 39 patients who
increased dose at week 4 remained at 8 mg/kg q4w for
the remainder of the study (identified as the tocilizumab
4/8 mg/kg subset). The other 23 patients were up-titrated
to the 8 mg/kg q4w dose at another time (n= 19) and/or did
not remain at the 8 mg/kg q4w dose for the duration of the
study as they were down-titrated to tocilizumab 4 mg/kg
q4w primarily because of adverse safety findings (n= 4).
In Study 1309, 101 patients were randomized and treated
with single doses of tocilizumab 4 mg/kg i.v. (n= 25), toci-
lizumab 8 mg/kg i.v. (n= 24), sarilumab 150 mg s.c. (n= 26)
or sarilumab 200 mg s.c. (n= 26). In both studies, all pa-
tients received concomitant csDMARDs (Supplementary
Table S3, available at Rheumatology online).
Safety
Adverse events
Within each study, the incidence of TEAEs was similar
between the sarilumab and tocilizumab groups (Table 2).
There were few serious AEs in either study, with no dis-
cernible patterns. In ASCERTAIN, there were two serious
infections in the tocilizumab group and one in the sarilu-
mab 200 mg q2w group; no serious infections were re-
ported in Study 1309. No opportunistic infections were
reported in either study. In ASCERTAIN, the most fre-
quently reported TEAEs were neutropenia, injection-site
erythema and nasopharyngitis in the sarilumab groups
and accidental overdose, upper respiratory tract infection
and nausea in the tocilizumab group (Table 3).
In ASCERTAIN, a numerically higher incidence of
TEAEs leading to treatment discontinuation was observed
with sarilumab [150 mg q2w, n= 6 (12.2%); 200 mg q2w,
n= 8 (15.7%)] than with tocilizumab [n= 4 (3.9%)]. Five
patients who received sarilumab discontinued because
of laboratory abnormalities (neutropenia, leucopaenia
and increased transaminases), which met protocol-
defined criteria for discontinuation; none of these labora-
tory changes were associated with clinical manifestations.
Three of these five patients had resumed their s.c. sarilu-
mab injections but were discontinued because their i.v.
infusion (placebo for tocilizumab) could not be resumed
within the protocol-specified window. No discontinuations
due to laboratory abnormalities were reported in the toci-
lizumab group. Two patients in each of the sarilumab
groups and one patient in the tocilizumab group discon-
tinued because of infections. Two patients who received
sarilumab 200 mg q2w discontinued because of injection-
site reactions and one patient who received sarilumab
200 mg q2w discontinued because of an infusion-related
reaction while receiving i.v. placebo. No clinical patterns
were observed for the remaining events that led to dis-
continuation of sarilumab. Two patients discontinued toci-
lizumab while receiving 8 mg/kg q4w because of
worsening RA (n= 1) and acute renal failure (n= 1), and
one patient discontinued after one dose of tocilizumab
4 mg/kg because of tremors. There was one death,
which was due to septic shock and occurred after one
dose of tocilizumab 4 mg/kg. The patient, a 64-year-old
woman with history of prior abdominal exploratory lapar-
otomy in 2005 (reason unknown) began to experience
bloody diarrhoea and intense abdominal pain 18 days
after receiving a single dose of tocilizumab. The patient
died the following day despite treatment with antibiotics,
vasopressors and mechanical ventilation. ANC 3 days
before the event was 4.75 giga/l (baseline 5.33 giga/l).
Concomitant medication included prednisone (7.5 mg
oral) and naproxen (500 mg oral). The medical report in-
dicted bowel infarction, and the death was adjudicated to
be due to septic shock in the context of most probable
mesenteric infarction.
In Study 1309, the rates of TEAEs were comparable in
the sarilumab and tocilizumab groups and were numeric-
ally higher for the higher doses compared with the lower
doses of sarilumab (200 mg, 46.2%; 150 mg, 38.5%) and
TABLE 2 Overview of treatment-emergent AEs in the multiple-dose, 24-week ASCERTAIN study and single-dose,
6-week Study 1309
ASCERTAIN Study 1309
AE
Tocilizumab
q4w i.v.
+ csDMARDs
(n= 102)a
Sarilumab 150 mg
q2w s.c.
+ csDMARDs
(n= 49)
Sarilumab
200 mg
q2w s.c.
+ csDMARDs
(n= 51)
Tocilizumab
4 mg/kg i.v.
+ MTX
(n= 25)
Tocilizumab
8 mg/kg i.v.
+ MTX
(n= 24)
Sarilumab
150 mg s.c.
+ MTX
(n= 26)
Sarilumab
200 mg s.c.
+ MTX
(n= 26)
AE 68 (66.7) 33 (67.3) 36 (70.6) 8 (32.0) 12 (50.0) 10 (38.5) 12 (46.2)
SAE 7 (6.9) 1 (2.0) 3 (5.9) 0 1 (4.2) 0 0
Serious infection 2 (2.0) 0 1 (2.0) 0 0 0 0
AE leading to death 1 (1.0) 0 0 0 0 0 0
AE leading to treatment
discontinuation
4 (3.9) 6 (12.2) 8 (15.7) 0 0 0 0
Values are n (%). aTocilizumab q4w i.v. starting at 4 mg/kg could be increased to 8 mg/kg based on clinical response as
assessed by the investigator. AE: adverse event; csDMARD: conventional synthetic DMARD; q2w: every 2 weeks; q4w: every
4 weeks; SAE: serious AE.
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tocilizumab (8 mg/kg, 50.0%; 4 mg/kg, 32.0%). TEAEs
occurring in >1 patient in any treatment group were neu-
tropenia, upper respiratory tract infection, headache,
thrombocytopenia and RA (Supplementary Table S4,
available at Rheumatology online). One patient in the toci-
lizumab 8 mg/kg group had a serious AE (hip fracture),
which was not considered treatment related. No deaths
were reported during the study, and no patients in any
treatment group discontinued because of an AE.
Laboratory changes
Laboratory changes in both ASCERTAIN and Study 1309
were consistent with IL-6R signalling blockade and
included decreases in neutrophil and platelet counts and
increases in transaminases and lipids (Table 4).
In ASCERTAIN, in which haematology assessments
were performed q2w, a numerically higher incidence of
ANC <1.0 giga/l was observed with sarilumab adminis-
tered q2w compared with tocilizumab administered q4w,
although the mean change in ANC in the sarilumab groups
was within the range observed with tocilizumab (Fig. 1A).
At week 24, the mean change in ANC was comparable
between patients receiving sarilumab 200 mg q2w and
those who increased their tocilizumab dose to 8 mg/kg
q4w. There was no evidence of an association between
decrease in ANC and increased incidence of infections.
In Study 1309, a dose-dependent effect on ANC
<1.0 giga/l was observed, with a higher incidence re-
ported in the high-dose sarilumab and tocilizumab
groups compared with the low-dose groups (Table 4).
Over days 17, there was no meaningful difference
across all treatment groups in the ANC parameters as-
sessed. The time to onset for decreased ANC and mag-
nitude of decrease were similar across the sarilumab and
tocilizumab groups for all doses. ANC decreased within a
few hours of dosing (Fig. 1B and C). The median time to
ANC nadir ranged from 3 to 5 days after administration;
mean nadir values ranged from 1.55 to 1.78 giga/l
across all treatment groups. The timing of the trend for
return to baseline was consistent with the dosing interval
for both sarilumab (q2w) and tocilizumab (q4w). By day
15, the approximate time that a second dose of sarilumab
would be given in a q2w dosing regimen, ANC values in
the sarilumab groups had increased but had not yet
returned to baseline. By day 29, the approximate time
that a second dose of tocilizumab would be given in a
q4w dosing regimen, ANC values had essentially returned
to baseline in the tocilizumab 4 mg/kg group but not
in the 8 mg/kg group. Decreases in ANC did not ap-
pear to be associated with an increased incidence of
infections.
Increased levels of ALT >3 upper limit of normal
occurred in few patients in either study. In ASCERTAIN,
the mean increase in ALT at week 24 was comparable
between the tocilizumab 4/8 mg/kg q4w and sarilumab
200 mg q2w groups, and increases in both groups were
slightly greater than in the sarilumab 150 mg q2w group
(Fig. 2). Incidence of ALT increases of 35 upper limit of
normal was comparable among the treatment groups and
reversible upon discontinuation of study treatment.
Platelet count <100 giga/l was reported in a single patient
receiving sarilumab 150 mg q2w in ASCERTAIN and in
two patients receiving sarilumab 150 mg in Study 1309;
none of the patients experienced bleeding related to
decreased platelet count. Incidence of total cholesterol
56.2 mmol/l in the sarilumab and tocilizumab groups
was generally similar in both studies. In ASCERTAIN,
mean increases in low-density lipoprotein cholesterol,
high-density lipoprotein cholesterol and triglycerides at
week 24 were of similar magnitude in all treatment
groups. Lipid-modifying agents (including statins) were
initiated on the same day or after the first dose in eight
patients (7.8%) in the tocilizumab group, two patients
(4.1%) in the sarilumab 150 mg q2w group and two
TABLE 3 Frequently reported treatment-emergent AEs in ASCERTAINa
AE
Tocilizumab q4w i.v.
+ csDMARDs (n= 102)b
Sarilumab 150 mg q2w s.c.
+ csDMARDs (n= 49)
Sarilumab 200 mg q2w s.c.
+ csDMARDs (n= 51)
Infection 32 (31.4) 20 (40.8) 11 (21.6)
Nasopharyngitis 4 (3.9) 6 (12.2) 3 (5.9)
Urinary tract infection 6 (5.9) 4 (8.2) 2 (3.9)
Upper respiratory tract infection 7 (6.9) 2 (4.1) 1 (2.0)
Gastroenteritis 1 (1.0) 3 (6.1) 0
Neutropenia 4 (3.9) 6 (12.2) 8 (15.7)
Injection-site erythema 1 (1.0) 4 (8.2) 4 (7.8)
Accidental overdosec 9 (8.8) 1 (2.0) 3 (5.9)
Dizziness 4 (3.9) 1 (2.0) 3 (5.9)
Hypercholesterolaemia 6 (5.9) 2 (4.1) 1 (2.0)
Nausea 7 (6.9) 1 (2.0) 1 (2.0)
RA 6 (5.9) 1 (2.0) 0
Values are n (%). aAt least 5% in any treatment group. bTocilizumab q4w i.v. starting at 4 mg/kg could be increased to 8 mg/kg
based on clinical response as assessed by the investigator. cAn overdose was defined as the administration of 52 sarilumab
doses in <11 calendar days or 52 tocilizumab doses in <21 calendar days or at least twice of the intended dose within the
intended therapeutic interval for sarilumab or tocilizumab. AE: adverse event; csDMARD: conventional synthetic DMARD; q2w:
every 2 weeks; q4w: every 4 weeks.
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patients (3.9%) in the sarilumab 200 mg q2w group. In
Study 1309, small mean increases from baseline in total
cholesterol, low-density lipoprotein cholesterol and trigly-
cerides observed at day 15 returned to baseline by day 29
in the sarilumab groups and remained slightly elevated in
the tocilizumab groups. There were no notable differences
in mean high-density lipoprotein cholesterol values.
Discussion
ASCERTAIN and Study 1309 were the first studies in
which sarilumab and tocilizumab were evaluated in pa-
tients with RA within the same study using multiple and
single doses, respectively, providing an opportunity to
understand the safety and tolerability of these two
agents within the same therapeutic class of IL-6R inhibi-
tors. Overall, no clinically meaningful differences were
observed regarding safety between sarilumab and tocili-
zumab in either study. The incidence and type of TEAEs
were similar for the sarilumab and tocilizumab groups in
each study.
In ASCERTAIN, the incidence of TEAEs leading to treat-
ment discontinuation was numerically higher with sarilu-
mab than with tocilizumab, but some of these
discontinuations were due to protocol-mandated criteria
related to laboratory changes; these laboratory changes
occurred without clinical manifestations. While most pa-
tients in the sarilumab groups who interrupted therapy
because of laboratory abnormalities resumed treatment
as these abnormalities resolved, three patients were dis-
continued because the protocol-mandated interval be-
tween i.v. infusions had been exceeded. There was no
clinical pattern for the non-laboratory TEAEs that led to
discontinuation, but the low number of events limits as-
sessment and interpretation of these data.
Upper respiratory tract infections and neutropenia were
among the most frequent TEAEs in both studies.
Laboratory changes in both studies were consistent with
IL-6R inhibition and included increases in lipids and trans-
aminases and decreases in neutrophil counts. Mean
changes in ANC in the sarilumab groups were within the
ranges observed in the tocilizumab groups.
The association between IL-6 signalling and the PD
marker ANC after a single dose of sarilumab or tocilizu-
mab was assessed in Study 1309. This assessment indi-
cated that despite differences in PK profiles due to route
of administration and 10-fold lower drug peak concentra-
tions with sarilumab s.c. compared with tocilizumab i.v.
(data not shown), similar rapid decreases in ANC (within
4 h), nadir values and median time to nadir values were
observed across all four treatment groups. ANC returned
towards baseline earlier with sarilumab than with tocilizu-
mab, which is consistent with drug concentrationtime
profiles. A dose-dependent effect on ANC <1.0 giga/l
was observed, with a higher incidence reported in the
high-dose sarilumab and tocilizumab groups versus the
low-dose groups. Decreased ANC was not associated
with an increased incidence of infections.
In ASCERTAIN, tocilizumab was administered i.v. ac-
cording to US product labelling [6]; patients were treated
with 4 mg/kg and the dose was increased at the discretion
of the investigator. In the study, 60% of patients received
at least one dose of tocilizumab 8 mg/kg. Because of dif-
ferences in the route of administration (s.c. for sarilumab,
i.v. for tocilizumab), PK profiles and dosing intervals (q2w
for sarilumab, q4w for tocilizumab) in relation to the sam-
pling schedule (q2w for haematology assessments), nu-
meric differences were observed in the incidence of ANC
<1.0 giga/l, a PD marker of IL-6 inhibition, between the
sarilumab and tocilizumab groups. Regardless, there was
no difference in the rates of infection or serious infection
between the tocilizumab and sarilumab groups.
The rapid and similar decrease in ANC with these IL-6R
inhibitors is potentially explained by redistribution from the
TABLE 4 Overview of laboratory changes in the multiple-dose, 24-week ASCERTAIN study and single-dose, 6-week
Study 1309
ASCERTAIN Study 1309
Patients
Tocilizumab
q4w i.v.
+ csDMARDs
(n= 102)a
Sarilumab 150 mg
q2w s.c.
+ csDMARDs
(n= 49)
Sarilumab 200 mg
q2w s.c.
+ csDMARDs
(n= 51)
Tocilizumab
4 mg/kg i.v.
+ MTX
(n= 25)
Tocilizumab
8 mg/kg i.v.
+ MTX
(n= 24)
Sarilumab
150 mg s.c.
+ MTX
(n= 26)
Sarilumab
200 mg s.c.
+ MTX
(n= 26)
ANCb
0.5<1.0, giga/l 1 (1.0) 2 (4.2) 5 (9.8) 3 (12.0) 6 (25.0) 4 (15.4) 6 (23.1)
<0.5, giga/l 0 1 (2.1) 0 0 0 0 1 (3.8)
ALTc
>35ULN 3 (3.0) 2 (4.3) 2 (3.9) 0 1 (4.2) 0 1 (3.8)
>5ULN 0 0 1 (2.0) 0 1 (4.2) 0 0
Platelet countd
<100, giga/l 0 1 (2.1) 0 0 0 2 (7.7) 0
Values are n (%). aTocilizumab q4w i.v. starting at 4 mg/kg could be increased to 8 mg/kg based on clinical response as
assessed by the investigator. bFor ANC in ASCERTAIN, n= 48 for sarilumab 150 s.c. cFor ALT in ASCERTAIN, n= 101 for
tocilizumab q4w i.v. and n= 47 for sarilumab 150 mg q2w s.c. dFor platelets in ASCERTAIN, n= 48 for sarilumab 150 mg q2w
s.c. ALT: alanine aminotransferase; ANC: absolute neutrophil count; csDMARD: conventional synthetic DMARD; ULN: upper
limit of normal.
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FIG. 1 Mean change from baseline in ANC ± S.E. by treatment and visit in (A) ASCERTAIN (weeks 124), (B) Study 1309
(days 129) and (C) Study 1309 (days 17)
aPatients in the 4/8 mg/kg q4w i.v. group increased their dose to 8 mg/kg at week 4 and remained on 8 mg/kg for the
remainder of the study. bThere were four sampling points on day 1: baseline, 1 h, 4 h and 8 h after dosing. ANC: absolute
neutrophil count; BL: baseline; q2w: every 2 weeks; q4w: every 4 weeks.
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vascular compartment and results in the uptake and removal
of circulating neutrophils without affecting their function [13].
In vitro evidence suggests that IL-6 increases circulating
neutrophils by releasing them from marginated pools in
bone marrow [14]. Thus, an anti-IL-6R agent may poten-
tially reverse this effect. The rapid onset and recovery of
the decrease in neutrophil count observed in Study 1309
provides support for this mechanism, and a PD model that
implemented neutrophil margination with ANC-specific
tolerance describes the mechanism of transient de-
creases in ANC observed with IL-6R inhibitors [15].
One limitation of ASCERTAIN is that robust character-
ization of the neutrophil kinetics (including identification of
the nadir) after multiple doses of sarilumab and tocilizu-
mab, as was done in Study 1309 after single-dose admin-
istration, could not be performed because of less frequent
PK and PD sampling. Therefore, Study 1309 provides
valuable insight into the similarities in changes in neutro-
phil parameters that occur with the two IL-6R inhibitors.
In summary, IL-6R inhibition leads to transient de-
creases in ANC, likely due to margination of neutrophils
from the circulation where the neutrophils remain present
and maintain their functionality if triggered. This phenom-
enon of margination is further supported by the fact that
no clinically meaningful consequence of the decrease in
ANC by IL-6R inhibitors has been identified.
Conclusions
Overall, no clinically meaningful differences were
observed with regard to safety between sarilumab and
tocilizumab in either study, including the incidence and
types of TEAEs. Laboratory changes (e.g. decrease in
ANC and increase in ALT) noted in the sarilumab groups
were within the same range as those noted in the
tocilizumab groups. Although numeric differences in inci-
dence of ANC <1.0 giga/l between the sarilumab and
tocilizumab groups were observed in ASCERTAIN, con-
sidering the results of Study 1309, this most likely reflects
differences in PK (related to route of administration; s.c.
for sarilumab and i.v. for tocilizumab) and dosing interval
(q2w for sarilumab versus q4w for tocilizumab) in relation
to the sampling schedule (q2w). Decreased ANC was not
associated with an increased incidence of infection.
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A blind man with an acute abdomen
A 32-year-old male presented to the emergency service
with acute periumbilical pain. He had a history of recurrent
oral and scrotal ulcers for the past 3 years and loss of
vision in both eyes for the past 2 years. On ophthalmolo-
gical evaluation, he was found to have right hypopyon and
bilateral retinal vasculitis. Abdominal ultrasonography re-
vealed a large globular mass at the umbilical region
suggestive of an aneurysm. A computed tomographic
angiogram of abdominal vessels revealed a large
(7.3 cm5.4 cm7.9 cm) pseudoaneurysm arising from
the posterior wall of the aorta at the level of origin of the
right renal artery, with self-contained rupture (Fig. 1(a)).
A diagnosis of vascular Behc¸et’s disease was made and
he was started on pulse methylprednisolone and cyclo-
phosphamide, and subsequently surgical repair of the an-
eurysm was performed (Fig. 1(b)).
Arterial involvement in Behc¸et’s disease is rare and
almost exclusively found in young males. Although pulmon-
ary artery aneurysm is a classical symptom of Behc¸et’s
disease, the abdominal aorta is the most common site [1].
Arterial involvement is a potentially fatal complication. Early
aggressive immunosuppressive therapy is essential for
good outcome. For aortic and peripheral artery involve-
ment, treatment with corticosteroid and cyclophosphamide
is necessary before surgical intervention [2].
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FIG. 1 (A) CT angiogram (sagittal view) of abdominal
vessels showing a large (7.3 cm5.4 cm7.9 cm) pseu-
doaneurysm arising from the posterior wall of the aorta at
the level of origin of the right renal artery, with self-con-
tained rupture. (B) Postoperative CT angiogram (sagittal
view) showing intact repair. Radio-opaque area behind
repaired rent is Teflon felt (polytetrafluoroethylene mater-
ial) used for reinforcement of repair (arrow).
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